ESR1 Mutations Prevalent in ER+ Metastatic Breast Cancer

Share this content:
ESR1 Mutations Prevalent in ER+ Metastatic Breast Cancer
ESR1 Mutations Prevalent in ER+ Metastatic Breast Cancer

Estrogen receptor α (ESR1) mutations are prevalent in patients with estrogen receptor (ER)-positive metastatic breast cancer treated with aromatase inhibitors, with particular mutations increasing the risk for more aggressive tumor biology, a study published in JAMA Oncology has shown.1

ESR1 mutations harbored by patients with metastatic breast cancer promote ligand-independent receptor activation and resistance to estrogen-deprivation therapy in preclinical models; however, the prevalence of these mutations and their effect on clinical outcomes is unclear.

For the study, investigators analyzed cell-free DNA from baseline plasma samples from 541 patients with metastatic breast cancer who participated in the phase 3 BOLERO-2 trial, which evaluated the efficacy and safety of exemestane plus everolimus vs exemestane plus placebo. All patients were postmenopausal women who had previously received an aromatase inhibitor.

Results showed that 21.1% of the 541 evaluable patients had ESR1 mutation D538G and 13.3% harbored the Y537S mutation. Thirty patients had both.

Researchers found that both mutations were associated with worse overall survival. Patients with wild-type ESR1 had a median overall survival of 32.1 months (95% CI, 28.09-36.40); those with the D538G mutation had a median survival of 25.99 months (95% CI, 19.19-32.36); Y537S conferred a survival of 19.98 months (13.01-29.31); and having both mutations was associated with a median survival of 15.15 months (95% CI, 10.87-27.43).

The study further demonstrated that patients harboring the ESR1 mutation D538G derived a similar progression-free survival from the addition of everolimus to exemestane compared with those with wild-type ESR1.


1. Chandarlapaty S, Chen D, He W, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer. JAMA Oncol. 2016 Aug 11. doi: 10.1001/jamaoncol.2016.1279. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs